AHF Dedicates New Westside Healthcare Center and Pharmacy on Wilshire Blvd.
LOS ANGELES--(BUSINESS WIRE)--After over three decades of care and service at its La Cienega Boulevard location, AIDS Healthcare Foundation (AHF) is pleased to announce the relocation of its Westside AHF Healthcare Center to a new state-of-the-art facility—part of AHF's innovative patient-centered clinic model eliminating waiting rooms—to nearby Wilshire Boulevard where it will continue delivering cutting-edge medical care and services to patients regardless of insurance status or ability to pay. The site also features a full service AHF Pharmacy.
AHF is pleased to announce the relocation of its Westside AHF Healthcare Center and AHF Pharmacy to a new state-of-the-art facility on Wilshire Blvd. in Beverly Hills—part of AHF's innovative patient-centered clinic model, which eliminates waiting rooms.
Share
"I'm proud to announce the opening of our newly reimagined Westside Healthcare Center, now operating under a patient-centered, open-concept model—with no traditional waiting room," said Dr. Carl Millner, AHF Chief Medical Officer. "This innovation is especially important for our patients living with HIV, who too often face stigma, delays, and unnecessary barriers to care. By eliminating the waiting room, we're creating a space that prioritizes immediacy, dignity, and seamless access to services. At AHF, we believe every patient deserves to feel respected and supported from the moment they arrive."
"Our new Westside Healthcare Center has no waiting room, so patients are immediately escorted to treatment rooms and serviced from a centrally located provider workstation," said Marcelino Alcorta, AHF Western Bureau Chief. "The goal is to maximize efficiency using this patient-centered model to improve health outcomes and increase retention in care."
According to the Los Angeles County Division of HIV and STD Programs (DHSP), there were 50,904 people living with diagnosed HIV in Los Angeles County by end of 2024. Of these individuals:
73% received medical care in 2024
54% were retained in care by the end of 2024
66% achieved viral suppression in 2024
93% achieved viral suppression in 2024 among those who had at least 1 viral load test during the year
1,635 were newly diagnosed with HIV in 2024
79% of new diagnoses in 2024 were linked to care within one month of diagnosis.
AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.3 million individuals across 48 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center's highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WebMD
36 minutes ago
- WebMD
FDA Approves First Twice-Yearly Shot to Prevent HIV
June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012, the drug – known as lenacapavir but sold under the name Yeztugo – offers a new way to protect against this life-threatening infection that affects more than a million people in the U.S. and has no cure. The shot is given before potential exposure to the virus. HIV spreads through unprotected sex and shared needles (including dirty needles from tattoos and body piercings). It weakens the immune system, and in its advanced stage, the body can no longer fight off infections, leading to acquired immune deficiency syndrome (AIDS). Only about a third of eligible people in the U.S. use available HIV prevention, with especially low use among women, Black/African American and Hispanic communities, and people in the South. This is mainly due to stigma, low awareness about existing options, and challenges with daily pills or frequent shots. Carlos del Rio, MD, a distinguished professor of medicine in the Division of Infectious Diseases at Emory University School of Medicine, said that getting a shot just twice a year could make it easier for people to stick with prevention. "Yeztugo could be the transformative PrEP [pre-exposure prophylaxis] option we've been waiting for – offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic," said del Rio, who is also co-director of the Emory Center for AIDS Research in Atlanta. Gilead, the drug's maker, said the FDA approved Yeztugo based on two major studies, which showed that it worked better than taking a daily pill form of PrEP in preventing HIV with a nearly 100% success rate. In one trial, none of the 2,134 women who received Yeztugo got HIV, while in the other, only two out of 2,179 people did. It was well tolerated with no new safety concerns, which led the academic journal Science to name lenacapavir as its 2024 "Breakthrough of the Year." Yeztugo attacks a protective shell that HIV needs to stay alive, which helps stop the virus from growing and spreading. Most HIV drugs only work at one part of the virus's life cycle, but Yeztugo works at several points. It also still works even if other HIV drugs have stopped working. It is given as a shot under the skin and is only for people who test negative for HIV. Before starting Yeztugo and before each shot, your provider will test for HIV to prevent the virus from developing resistance to the medication. The treatment begins with two shots and two tablets, followed by two more tablets the next day – then continues with one shot every six months. If a shot is delayed by over two weeks, a weekly pill can be used for up to six months. If over 28 weeks pass with no treatment, patients may need to restart. If a patient gets HIV while on Yeztugo, they'll need full HIV treatment, as Yeztugo alone isn't enough. Yeztugo helps lower the risk of HIV when taken as prescribed, along with safe sex practices like using condoms.
Newsweek
3 hours ago
- Newsweek
HIV: Supercharged Vaccine Could Protect Well With Just One Dose
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A supercharged HIV vaccine could offer strong protection with just one injection, a study in mice has indicated. Developed by researchers from the Massachusetts Institute of Technology (MIT) and the Scripps Research Center, the vaccine includes two "adjuvants"—materials that help stimulate the immune system response. In the experiments, the dual-adjuvant vaccine was found to produce a wider diversity of antibodies to protect against an HIV protein than with either single adjuvant or none at all. This was because the vaccine accumulated in the mice's lymph nodes and remained there for a month—giving their immune systems more time to build up antibodies against HIV. "What's potentially powerful about this approach is that you can achieve long-term exposures based on a combination of adjuvants that are already reasonably well-understood, so it doesn't require a different technology," said paper author and MIT chemical engineer professor J. Christopher Love in a statement. And, the researchers said, the same approach could be used to create one-shot-only vaccines against other diseases, including COVID-19 and influenza. A man receives a vaccination. A man receives a vaccination. Rani Nurlaela Desandi/iStock / Getty Images Plus Most vaccines administered today are accompanied by adjuvants to help make them more effective. One often used with protein-based vaccines—such as given against hepatitis A and B—is "alum," short for "aluminum hydroxide." Alum activates the body's innate immune response, helping it to form a stronger memory of the vaccine antigen in case of a real infection. The new HIV vaccine combines alum with a nanoparticle known as SMNP, which itself combines the FDA-approved, naturally derived adjacent saponin with an inflammation-promoting molecule. In their study, the researchers found that the SMNP–alum combination helped the HIV protein in their vaccine both penetrate the protective layer of cells surrounding the lymph nodes without being broken down, as well as stay intact in the nodes for up to 28 days. The lymph nodes are where protective "B cells" are exposed to antigens—the substances that the body uses to recognize a given infection—and learn to produce the antibodies to fight back. Vaccine antigens (pink) concentrate in B cell follicles (cyan) Vaccine antigens (pink) concentrate in B cell follicles (cyan) MIT "As a result, the B cells that are cycling in the lymph nodes are constantly being exposed to the antigen over that [up to 28 day] time period—and they get the chance to refine their solution to the antigen," Love explained. He added: "When you think about the immune system sampling all of the possible solutions, the more chances we give it to identify an effective solution, the better." When the researchers analyzed the RNA of the B cells from the vaccinated mice, they found that those who had received both adjuvants had produced a more diverse array of B Cells and antibodies than the other rodents. In fact, those who received the dual-adjuvant vaccine produced more than twice as many unique B cells than those mice who received a single-adjuvant vaccine. This, the team explained, increases the odds that the mice's immune systems will be able to produce antibodies against a variety of strains of HIV in the case of a future injection. And the benefits of the dual-adjuvant tactic is not just limited to fighting HIV. "This approach is compatible with many protein-based vaccines, so it offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, SARS-CoV-2, or other pandemic outbreaks," said Love. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about HIV? Let us know via health@ Reference Rodrigues, K. A., Zhang, Y. J., Lam, J., Aung, A., Morgan, D. M., Romanov, A., Maiorino, L., Yousefpour, P., Gibson, G., Ozorowski, G., Gregory, J. R., Amlashi, P., Van, R., Buckley, M., Ward, A. B., Schief, W. R., Love, J. C., & Irvine, D. J. (2025). Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion. Science Translational Medicine, 17(803).
Associated Press
5 hours ago
- Associated Press
PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
GOLDEN, Colo.--(BUSINESS WIRE)--Jun 19, 2025-- PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has entered into an agreement with Immuno Cure, a prominent developer of DNA vaccines. Under the terms of the agreement, Immuno Cure will use PharmaJet's Tropis ID system in a human clinical trial to deliver their novel HIV-1 therapeutic DNA Vaccine (ICVAX). The agreement was executed on June 16, 2025, during a signing ceremony at the 2025 BIO International Convention in Boston, Massachusetts. This press release features multimedia. View the full release here: Dr. Xia Jin, CEO and Co-Founder of Immuno Cure, and Mr. Dan Mallon, Senior Vice President of Corporate Development of PharmaJet, captured the memorable moment after signing the MTA 'HIV Therapeutic DNA Vaccine (ICVAX) Clinical Study'. The study follows the successful first-in-human ICVAX Phase 1 clinical trial that showed exceptional safety and promising immunogenicity profiles. 3 The vaccine represents a significant step towards achieving virological control by ICVAX without antiretroviral therapy and ultimately becoming a functional cure of human immunodeficiency virus (HIV)/AIDS. Immuno Cure is investigating the potential for the Tropis ID system to improve the DNA vaccine performance and patient's clinical experience. Intradermal delivery is expected to help elicit long-lived and cross-reactive immune responses. The Tropis system easily leverages the rich network of dendritic cells, macrophages and T cells in the dermal layer and can provide a more potent and broader immunogenic response than vaccinating into the muscle. 1 Tropis is commercially scaled, has been used for over 12 million injections, and is the first and only needle-free ID delivery technology to achieve World Health Organization (WHO) prequalification. Dr. Xia Jin MD PhD, CEO of Immuno Cure, said, 'At Immuno Cure, our mission is to advance transformative therapies for infectious diseases and cancer. We are excited to partner with PharmaJet and leverage their Tropis Needle-free Injection System on our HIV therapeutic DNA vaccine program. We value innovative approaches that could enhance patient experience and vaccine performance.' 'This agreement adds to our portfolio of global development partnerships with innovative oncology and infectious disease developers. Our partners are joining our call to challenge antiquated IM administration methods in favor of ID delivery based on the growing body of evidence 4 demonstrating improved immune responses and safety profiles,' said Dan Mallon, Senior Vice President Corporate Development, PharmaJet. 'PharmaJet's needle-free technology is safe and well-tolerated and has shown to enable immune responses that are robust and durable.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis ® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About Immuno Cure Immuno Cure is a clinical-stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA Vaccine, Anti-Δ42PD1 Antibody and Vaccine Delivery Platform. To learn more about Immuno Cure, please visit: View source version on CONTACT: Nancy Lillie [email protected] 1-888-900-4321 Option 3 KEYWORD: HONG KONG UNITED STATES NORTH AMERICA ASIA PACIFIC MASSACHUSETTS COLORADO INDUSTRY KEYWORD: MEDICAL DEVICES INFECTIOUS DISEASES GENETICS CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH ONCOLOGY SOURCE: PharmaJet Copyright Business Wire 2025. PUB: 06/19/2025 10:10 AM/DISC: 06/19/2025 10:09 AM
